Live Breaking News & Updates on Iontech

Stay informed with the latest breaking news from Iontech on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Iontech and stay connected to the pulse of your community

Biopharma Stock Breaking News - BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation

Biopharma Stock Breaking News - BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation

China , Germany , Shanghai , United-states , Fosun-pharma , Vivian-gu , Roche-group , Genentech , Pfizer , Duality-biologics-suzhou-co-ltd , Exchange-commission , Business-development

Bragar Eagel & Squire, P.C. Reminds Investors That Class

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

New-york , United-states , California , South-carolina , Bragar-eagel-squire , Marion-passmore , Brandon-walker , Mercury-systems-inc , Tesla-inc , Optics-corporation , Pfizer , Nasdaq

BioNTech challenges AstraZeneca with breast cancer precision drug trial

BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo. COVID-19 vaccine maker BioNTech, which is renewing its focus on its traditional roots in oncology, said in a joint statement with China's Duality that their drug would be tested on women with a certain type of advanced breast cancer with low levels of a cell surface receptor known as HER2. Partners Astra and Daiichi have taken the concept further with their leading drug Enhertu, based on the antibody-drug conjugate technology, a type of high-precision chemotherapy.

Frankfurt , Brandenburg , Germany , China , Ludwig-burger , Daiichi-sankyo , Roche-herceptin , Astrazeneca , Duality-biologics , Partners-astra , Louise-heavens , Breast-cancer

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Market forces rained on the parade of BioNTech SE ( NASDAQ:BNTX ) shareholders today, when the analysts downgraded...

Revenue-estimates , Arnings-per-share , Iontech , Rice-target , Evenue-decline ,

BioNTech Issues 2024 Revenue Guidance

BioNTech SE (BNTX) said it projects total company revenues of approximately 3 billion euros for financial year 2024, mainly driven by the COVID-19 vaccine franchise which is expected to remain profitable given the cost sharing structure with its partner Pfizer Inc.

Ugur-sahin , Pfizer-inc , Earnings , Uidance , Evenue , Iontech , Ntx ,

BioNTech inaugurates first manufacturing plant for mRNA vaccines in Rwanda

BioNTech, a leading biotechnology company, on Monday inaugurated its first manufacturing plant for mRNA vaccines in Africa in Rwanda capital of Kigali.....

Rwanda , Germany , Barbados , Senegal , Kigali , W09- , Ghana , Rwandan , German , Mia-amor-mottley , Nana-akufo , Xinhua-biontech

La Trobe University to host mRNA and AI facilities

BioNTech will develop and commission a state-of-the-art mRNA clinical-scale manufacturing facility at La Trobe University's Melbourne campus.

New-zealand , Australia , Melbourne , Victoria , Bundoora , La-trobe , Tasmania , Australian , Jacinta-allan , Wei-xiang , Trobe-university-melbourne , Trobe-university

Rescinded or not, ex-military members still ask SCOTUS to take up Defense Dept's COVID vax mandate

The Defense Department's COVID-19 vaccine mandate has been rescinded, but two ex-service members are still asking the Supreme Court to consider its constitutionality – in a case with the potentiality

Colorado , United-states , Dan-robert , Robert-califf , Neil-gorsuch , Clarence-thomas , Lloyd-austin , R-davis-younts , Hollie-mulvihill , Brandi-king , Pfizer , Defense-department

BioNTech says European Patent Office has declared Moderna patent invalid

COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer. "We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement. "The European Patent Office’s decision is an important one as we believe that this and others of Moderna’s patents do not meet the requirements for grant and should never have been granted," it added.

Germany , Frankfurt , Brandenburg , German , Matthias-williams , Ludwig-burger , Pfizer , European-patent-office , European-patent , Iontech , Uropean-patent , Oderna

BioNTech licenses bispecific antibody for cancer in $1 billion deal

The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.

China , Chinese , Xiaolin-liu , Pfizer , Antibody-drug-conjugates , Io-developments , Ipelines , Ispecific-antibodies , Onoclonal-antibodies , Iotechnology , Ell-culture , Harmacology